Skip to main content
. Author manuscript; available in PMC: 2014 Feb 10.
Published in final edited form as: Cytotherapy. 2010 Apr;12(2):178–189. doi: 10.3109/14653240903493409

Figure 2.

Figure 2

Box-plots showing flow cytometric evaluation of selected CD34+ cells that co-express CD133, CD309 (VEGFR2) and CD339 (Jagged-1). The median percentage purity of the CD34-selected cells was 82.5%; 70% of the cells co-expressed CD133 antigen. Less than 5% of the CD34+ cells co-expressed CD309 and CD339 (n=22).